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Abstract The label ‘Translational Research’ (TR) has become ever more popular
in the biomedical domain in recent years. It is usually presented as an attempt to
bridge a supposed gap between knowledge produced at the lab bench and its use at
the clinical bedside. This is claimed to help society harvest the benefits of its
investments in scientific research. The rhetorical as well as moral force of the label
TR obscure, however, that it is actually used in very different ways. In this paper,
we analyse the scientific discourse on TR, with the aim to disentangle and critically
evaluate the different meanings of the label. We start with a brief reconstruction of
the history of the concept. Subsequently, we unravel how the label is actually used
in a sample of scientific publications on TR and examine the presuppositions
implied by different views of TR. We argue that it is useful to distinguish different
views of TR on the basis of three dimensions, related to (1) the construction of the
‘translational gap’; (2) the model of the translational process; and (3) the cause of
the perceived translational gap. We conclude that the motive to make society benefit
from its investments in biomedical science may be laudable, but that it is doubtful
whether the dominant views of TR will contribute to this end.
Keywords Translational research  Translational medicine  Biomedical
innovation  Conceptual analysis  Science—society relationship
A. L. van der Laan (&)  M. Boenink
Department of Philosophy, Faculty of Behavioural Sciences, University of Twente,
P.O. Box 217, 7500 AD Enschede, The Netherlands
e-mail: a.l.vanderlaan@utwente.nl
123
Health Care Anal (2015) 23:32–49
DOI 10.1007/s10728-012-0236-x
Introduction
Translational Research—as well as Translational Medicine and Translational
Science—has become a buzzword in the field of biomedical science.1 It shows up in
the names of an increasing number of articles, reports, journals, research initiatives,
research institutes and educational programmes in the domain of medical
innovation. This rise went hand in hand with—and was probably partly motivated
by—an increasing interest for the concept in medical research policy. Policy makers
and funding institutions in several countries diagnosed a ‘gap’ that needs to be
‘bridged’ [11]. On the one side of that gap are the life sciences, producing enormous
amounts of knowledge and insights about health and illness on a molecular level.
On the other side there is clinical medicine, the domain that is expected to benefit
from those scientific advances, but instead only sparsely progresses. ‘Translational
Research’ (TR) is claimed to bridge those two sides.
A closer look at what TR in the biomedical domain is actual taken to be,
however, reveals a huge diversity. Differences appear already in the short slogans
that are often used to show what is TR about, such as: ‘‘Taking research from bench-
to-bedside’’ [27]; ‘‘Bridging basic research and medical innovation’’ [21];
‘‘Translating research into medical practice […]’’ [48]; ‘‘Translating science into
better healthcare’’ [17]. When turning to the actual activities that are presented
under the label of TR, an even more heterogeneous set passes by: the development
of biomarkers, performing first clinical studies of a new technique, the marketing of
a newly developed medical technology, the formulation of clinical guidelines or the
integration of different types of knowledge, to name just a few.
Moreover, as several authors have noted, the label TR is not a neutral description
of those diverse kinds of activities; it has a strong rhetorical as well as moral force
[65, 78]. The value of TR seems to be incontestable, resulting in a ‘‘translational
ethos’’ in biomedical science [50] or even in an obligation for biomedical
researchers [19]. Performing TR seems currently the right thing to do for a
biomedical scientist. Both Maienschein et al. and Denholm and Martin interpret this
shift in scientific morality in terms of a change in the contract between science and
society. Different from earlier generations, current citizens and governments distrust
public investments in science. They want value for money, and TR is supposed to
increase the chance of achieving such value. Since the plea for TR carries such a
strong normative force, it is worthwhile to reflect on what ‘Translational Research’
is taken to mean in the biomedical domain, and how it is supposed to contribute to
public benefit. In this paper we want to provide such reflection.
Up to now, the phenomenon of TR has received remarkably limited attention
from the social sciences and humanities. There is some literature on ethics and TR,
mainly focusing on research ethical issues [35, 39, 73]. In addition, there are a few
sociological studies of TR, often analysing interactions between different actor
groups involved in TR [13, 43, 49, 60, 78]. In both cases, usually a specific concept
1 As far as we can judge on the basis of the literature studied, these labels are used interchangeably in the
biomedical domain. Although our study includes documents using all three terms, for purposes of brevity
we will use the term ‘Translational Research’ only. To be clear, whereas this term might be used in other
domains as well, our analysis is limited to the way these terms are used in the biomedical domain.
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of TR is either implicitly or explicitly taken as a starting point. However, as
indicated above, the meaning of TR should not be taken for granted. As some
authors suggest, an in depth qualitative study of the various manifestations of TR is
needed to better understand the ethos of TR [66].
In this article we want to take a broader as well as a more analytical view. We
start with a brief reconstruction of the history of the concept ‘translational research’
in the biomedical domain. Subsequently, we unravel how the label is actually used
in biomedical scientific discourse. We argue that it is useful to disentangle different
views of TR by distinguishing three dimensions, related to (1) the construction of
the ‘translational gap’; (2) the model of the translational process; and (3) the cause
of the perceived translational gap. We will critically discuss the presuppositions of
the positions found for each dimension. Finally, we will ask how plausible it is that
the conceptions of TR dominant in the scientific literature will indeed help society
to harvest benefits from biomedical science.
Translational Research in the Biomedical Domain: Its History in a Nutshell
As a simple search for the term ‘translational research’ in Pubmed illustrates,2 the
label appeared for the first time in biomedical journals around 1993. Only from
about the year 2000 onwards the number of medical-scientific publications on TR
starts to grow exponentially (see Fig. 1).
Fig. 1 Number of published articles with the terms ‘‘Translational Research’’, ‘‘Translational Science’’
or ‘‘Translational Medicine’’ each year, as appeared in a Pubmed search (carried out September 9, 2011)
2 The PubMed search was carried out with the following terms: ‘‘translational research’’[All Fields] OR
‘‘translational medicine’’[All Fields] OR ‘‘translational science’’[All Fields]. We filtered our search by
data, which up to ‘‘1992/12/31’’ yielded no hits. From 1993 onwards we noted the hits per year by adding
‘‘AND ‘‘YEAR/01/01’’[PDAT] to ‘‘YEAR/12/31’’[PDAT]’’. Carried out September 9, 2011.
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All early publications using the term deal with cancer research (see for example:
[10, 54, 56, 57, 62, 83]. This can be attributed to the Specialized Programs of
Research Excellence (SPOREs), established by the U.S. National Cancer Institute
(NCI) in 1992. In response to growing concerns that scientific knowledge was not
always directly and effectively applied to reduce the burden of cancer, these
programs encouraged TR for different kinds of cancer [54, 58]. The SPOREs were
supposed to:
promote interdisciplinary research and to speed the bi-directional exchange
between basic and clinical science to move basic research findings from the
laboratory to applied settings involving patients and populations [58].
The NCI also was the first to link the term TR to the phrase ‘from bench to
bedside’, as it can be seen in the following definition of TR by NCI director Broder
and his colleague Cushing:
Translational research moves knowledge about cancer in either direction,
between findings at the laboratory bench and clinical observations at the
bedside. Both preclinical and clinical research are translational if the specific
goal is to move the fruits of basic knowledge closer to clinical application
[10].
After 1993, then, the term started to pop up in biomedical articles on cancer
research. The label at this time was used, for example, for research on the discovery
and validation of biomarkers as promising surrogate endpoints for cancer prevention
research [57]. Using biomarkers was argued to have great potential for accelerating
and reducing the costs of developing effective cancer prevention strategies. Around
1997, the label TR for the first time appeared in the name of cancer research centres
in Canada and North America. Such centres sought to facilitate TR by starting tissue
banks and by creating alliances between researchers working on different stages of
cancer research, as well as between scientists and private partners. In subsequent
years, the term was taken up outside the USA and Canada, and also in other
disciplines, such as AIDS research [32], cardiology [9] and gastroenterology [69].
TR slowly lost its unique association with cancer research and was increasingly put
forward in all areas of biomedical research.
A crucial turning point in the history of TR is the year 2003, when the American
National Institutes of Health presented the Roadmap for Medical Research. This
Roadmap claimed to address the ‘‘critical scientific gaps’’ blocking the transfor-
mation of discoveries in the life sciences into improvements in health [84]. In
subsequent years, other countries took similar initiatives. For example, the British
Medical Research Council (MRC) started to show interest in TR, understood as
research ‘‘accelerating the translation of fundamental research into benefits for the
person, in health and disease’’ [53]. In the Netherlands, the Advisory Council on
Health Research (RGO—Dutch acronym) wrote a report in which the strengths and
weaknesses of the Dutch research system with regard to TR are mapped. The RGO
describes TR as: ‘‘a phase in the knowledge chain. It comprises all steps from the
identification of possible leads (in patients or patient material) for diagnostics,
prevention or treatment, up and including early application in clinical practice.
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Research questions may originate from clinical practice as well as from the
laboratory’’ [1]. And in 2009 the EU established the European Advanced
Translational Research Infrastructure in Medicine (EATRIS), in which ten
European countries participate [4, 21]. EATRIS aims to ‘‘provide infrastructure to
allow a faster and more efficient transfer of research discoveries into new products
to prevent, diagnose or treat diseases’’ [21].
From 2003 on, then, TR has appeared high on the policy agenda for biomedical
research in a growing number of countries. However, by then the motivation to
stimulate TR seems to have slightly shifted. The first TR-initiatives were driven by
the desire to finally see effective treatment for an awful disease. The more recent
initiatives start from the observation that health improvements have not kept up with
the increased speed of discovery in the life sciences, such as genomics and
molecular biology. The completion of the Human Genome Project (still quite recent
then) definitely played a role here. After all, this lavishly funded ‘big science’-
project did not bring about the promised revolutionary changes in health care or the
expected health gains. Recent pleas for TR are thus partly rooted in disappointment
about the societal profit from basic research.
Whatever its motivation, the popularity of TR in research policy circles clearly
affected the biomedical research domain. Research centres were set up, journals
were launched, research infrastructures were built and educational programmes
were developed, all devoted to TR. It is no surprise, then, that the number of
scientific articles on TR grew exponentially (see Fig. 1). However, the quantitative
picture is misleading. Looking beyond the label itself, it quickly becomes visible
that TR is interpreted in very different ways. To evaluate what the rise of the label
TR actually means, we should first disentangle its different meanings.
Methods
Since the literature on TR is booming, we analysed a sample of documents. We
focus on the biomedical scientific literature, and not on the science policy
documents, because the first shows how the label is used by those most directly
involved in doing TR. Science policy documents, in contrast, reveal more about
ideals than about actual activities. We started with the set of literature identified by
the PubMed search described above. We limited the results first by selecting those
publications published in ‘core clinical journals’. These journals have been indexed
by the U.S. National Library of Medicine as high quality clinical English language
journals. From this set, we further selected those publications in which the term TR
(or Translational Science/Translational Medicine) is used in the title of the
publication.3 This resulted in a set of 107 articles published between 1993 and 2011.
The collection comprises a mixture of editorials and commentaries in which the
concept of TR is more or less explicitly reflected upon, and research articles in
which results and findings of so-called ‘TR’ are reported.
3 Search details: ‘‘Translational Research’’[Title] OR ‘‘Translational Medicine’’[Title] OR ‘‘Translational
Science’’[Title] AND jsubsetaim[text]. Carried out December 19, 2011.
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We analysed this sample asking two questions. First, since translation implies
that one thing is translated into something else, what are the domains supposed to be
in need of communication? And secondly, which activities are thought to achieve
translation? We found that a huge variety of activities, by very different actors in
different practices, is labelled ‘TR’. Subsequently, we identified three dimensions
that are helpful to distinguish different views of TR. First, it is useful to ask how the
perceived ‘translational gap’ is actually constructed. Secondly, the translational
process is modelled in very different ways. Finally, the perceived cause(s) of the
translational gap deserve attention. We will discuss each dimension and the
different positions found on that dimension in the subsequent sections.
Which Translational Gap?
The metaphor of translation suggests that TR deals with at least two domains: A is
translated into B. But what is in need of translation? And into what should it be
translated? Or, to phrase it differently, what are the two sides supposed to constitute
the gap in need of a bridge?
One side of the gap (let’s call it side 1) is identical in most publications on TR. It
is referred to with terms like ‘new knowledge’ (also: ‘research findings/discoveries/
ideas/insights/information’) gained from ‘basic (biomedical) research’ (also:
‘animal studies/in vitro studies/pre-clinical studies’). Although the range of
scientific disciplines and research methods supposed to yield such knowledge
slightly varies, the general idea remains the same: the knowledge to be translated
comes from pre-clinical studies, in which the human body was not yet involved.
The variety of interpretations of TR appears only when the other side (side 2) of
the translational gap is pointed out. We identified six variants for side 2 in the
documents we consulted. The different constructions of the gap are described in
Table 1, illustrated by a characteristic quote.
This overview shows that the gap TR is supposed to bridge can be constructed in
rather narrow as well as quite broad ways. Many documents stick to a narrow
conception, in which TR should bridge a gap between basic science on the one hand,
and new approaches for pre- clinical work, knowledge of the human body or
medical applications on the other. The gap in these cases is situated within R&D
practice, or rather between many different R&D practices. The conceived result of
TR is more (different) knowledge, or a new technology. A smaller, but not
negligible number of publications wants TR to address a much wider gap, between
basic science on the one hand and clinical practice or the actual health condition of
individuals and populations on the other. In these cases, the gap spans beyond R&D
practices, pointing out that innovative knowledge and products are not automat-
ically used once available. This difference between narrow and broad conceptions
of the translational gap has been noticed before, and is sometimes indicated by
distinguishing T1 (narrow) and T2 [82] or even T1 (narrow) and T2, T3 and T4
(different varieties of broad TR) [38].
When discussing TR, then, one should be aware that there is not just one
translational gap; there are many gaps. Clearly, what TR is supposed to do and aim
for depends on the way this gap is constructed. For any publication on TR it makes
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sense to question which gap TR is actually supposed to address. The broader the
gap, the more complex and multifarious TR becomes. In the broader views TR is not
just about translating one type of knowledge into another kind of knowledge, as is
more or less the case when side 2 is identified with A or B. It can also be about
translating knowledge into (better) technologies, practices, bodies (or persons), and
social statistics. With each subsequent broadening of the gap, the potential obstacles
to translation increase in kind and number, and achieving translation will therefore
take more and different types of efforts. Bridging the broader gaps requires that
practices and habits have to be reshaped and that roles and responsibilities of
various actors have to be changed. Accordingly, a broad construction of the
translational gap tends to interpret TR in an extremely comprehensive as well as
ambitious way.
Defining the gap in a narrow way, as most of the documents in our sample do, has
definite advantages. It implies a relatively unambiguous and maybe more feasible
conceptualization of TR. However, the broader constructions of the translational
gap rightly remind us that the value of new biomedical knowledge or of a new
biomedical technology lies in its effects on our health. The additional activities
included in the broader conceptions of TR therefore do not replace, but are added to
the activities of the narrower views: they complete the picture of what is necessary
to harvest the promised values (usually health and quality of life, but there may be
others as well). When TR is conceptualized in a narrow way, it risks to loose sight
of what is necessary to make knowledge or applications valuable for individual
users and society. This risk is indeed visible in the documents we studied.
Repeatedly, the objectives of a publication are framed in a broad way, whereas the
endpoints chosen in the described research address narrow gaps only. Stu¨ve et al.
[75] for example, review the advances in ‘translational research’ in the area of
Table 1 The construction of translational gaps
Side 1 Side 2 Example
Results from new knowledge





‘‘[…] translating understanding into entirely
new approaches to therapy’’ [6]
B) Knowledge of
the human body
‘‘[…] investigations in humans which define the
biology of disease’’ [55]
C) Medical
applications
‘‘[…] to translate more quickly the myriad
discoveries in biomedical research into more
effective applications relevant to human




‘‘[…] to improve the application of scientific
discoveries from ‘‘the bench’’ to actual patient
care at ‘‘the bedside’’ […]’’ [22]
E) Benefit for the
individual
patient
‘‘[…] translation of […] scientific knowledge
into patient benefit […]’’ [25]
F) Improvement
of public health
‘‘From evidence based medicine to sustainable
solutions for public health problems’’ [47]
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multiple sclerosis. A narrow view on TR becomes visible: the review centralizes the
need for good animal models to evaluate newly developed therapies. Still, it is
argued that such models ‘‘will ultimately benefit patients’’ (p. 1312)—reflecting
broader aims of TR. The same can be seen in Lainka et al. [42], in which the term
TR refers to efforts of setting up integrative databases and international research
networks in order to get a better understanding of auto-inflammatory diseases.
Despite this narrow and rather specific use of the term of TR, the authors argue that
their work will allow ‘‘translation of newly discovered pathogenic mechanisms […]
into improvements in patient care […]’’ (p. 241). These examples implicate a lack
of attention for further work needed to harvest the potential value of their research.
In that sense, references to the term TR are in danger of becoming a facile self-
justification. Similar mismatches are even more problematic in research policy,
when huge budgets are spent on narrow translational research, whereas activities
addressing the broader variants of the translational gap are neglected.
Models of the Translational Process
The second dimension useful to distinguish different interpretations of TR is the
underlying model of the translational process. Here three positions can be
recognized: a linear view, a bi-directional, and a complex view. A majority of
the literature on TR seems inspired by a linear model of innovation. TR is then seen
as a sequence of steps, in which realization of the last aim (individual or public
health) is dependent on realizing the preceding ones. Many authors distinguish
different steps or phases in TR [28, 31] or speak of a ‘‘TR continuum’’ [7, 20]. The
different steps could be represented as follows (Fig. 2).
The underlying idea is that innovation starts with basic science. The knowledge
that results from basic science is then supposed to be translated in ideas and
knowledge about real (diseased) bodies and in medical technologies, that have to be
implemented in clinical practice. This will then result in healthier individuals and
improved public health.
Such a linear model of innovation is of course well known and ubiquitous in
discourse about innovation, both in R&D, science policy making and economics
[26]. It has definite advantages, because it orders the different stages of innovation
on a timescale and suggests a clear division of labour, thus indicating a seemingly
logical way to organize work on future innovation. However, it has also been
disqualified as empirically inadequate. Stokes [74] for example, discusses the
inadequateness of the commonly held distinction between basic and applied science
and their supposedly temporal, linear relationship. He points out that something like
‘‘use-inspired basic research’’ had a significant role in the history of biomedical
innovation. This type of scientific research is driven by anticipated use right from
Fig. 2 Translational research as a linear process of different succeeding steps
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the start. He mentions the work of Louis Pasteur, which substantially contributed to
both fundamental understandings in microbiology and advances in the treatment of
bacterial diseases, as an example of such use-inspired research. In addition, Bijker
[8] shows how social groups ‘pull and push’ [34] the process of technology
development in various directions, which is difficult—if not impossible—to predict.
In retrospect, then, innovation may appear to be a linear process, but such a
reconstruction disregards that ‘‘the ‘‘successful’’ stages in the development are not
the only possible ones’’ [64].
The linear model is not only empirically inadequate to describe innovation
processes, however. Several studies show that the division of labour and the timing
suggested by the linear model, when used prospectively, may actually block
successful innovation. A lack of attention for implementation, regulatory or ethical
issues during early phases of innovation may cause failure in implementation or lack
of acceptance [24, 44]. Views of TR that conceptualise translation as a linear,
unidirectional process thus risk to be unfruitful or even counterproductive.
Although a linear view of the translational process is dominant, a substantial
subset of the documents we analyzed stresses that translation should go in two
directions. In fact, the conception of TR as a two-way road was already brought
forward in the NCI definition cited above. Many authors argue that a unidirectional
view on translation neglects that basic science and technology development can
learn from and integrate findings from experiments, clinical studies, and even from
knowledge from clinical practice and from population studies. They claim that
‘backwards translation’ is necessary.
This ‘backwards translation’ can be conceptualized in a narrow or a broad(er)
way. Narrowly defined it means that results from knowledge produced in a specific
stage of research (like clinical trials) has to be ‘fed back’ to earlier phases of the
research process (like lab research) [14, 37]. The type of information translated
backwards is limited to scientific knowledge and translation takes place within the
R&D domain. This narrow conception of backwards translation is reminiscent of the
‘empirical cycle’ of research, in which scientific results inspire new hypotheses for
subsequent projects.
Documents advocating broader approaches of backwards translation argue that
early phases of innovation should also account for knowledge related to clinical
practice, individual and/or population behaviour. The range of proposals with regard
to whose and which knowledge to communicate includes: issues ‘relevant to routine
care delivery’, provided by primary care clinicians [22]; knowledge derived from
clinical practitioners and community settings [28]; results from observational
studies, epidemiology studies, social and behavioral sciences, and cost-effectiveness
studies [45, 52] and patient preferences [31]. There are also pleas to engage end-
users [29, 33, 67] and communities [68, 86] in establishing research agendas and
priorities, in study design and in the whole innovation trajectory. Some authors even
go beyond the image of two way traffic and characterize the translational process as
‘multidirectional’, ‘iterative’ and ‘dynamic’, thus stressing its complexity [19, 29,
52]. The translational process is then regarded as a continuous data exchange within
and between various research and non-research practices.
40 Health Care Anal (2015) 23:32–49
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The idea behind proposals for backwards translation in a broad sense, as well as
the multidirectional and dynamic views of the innovation process, is that
‘translation’ will be more successful when researchers account for information
from practices, actors and communities that may be affected by the products of
R&D. On the one hand, backwards translation may improve the future translat-
ability of new knowledge and innovations by anticipating relevant features of its
context of use (whether the human body, clinical practice or patients’ lives). This
will make innovations more useable for the projected users. On the other hand,
backwards translation may help to figure out early how innovations will best fit the
needs and values of those they affect. This makes innovations more relevant to the
projected users.
Backwards translation, in particular the broad version, can thus be a valuable
extension of the linear model still guiding a lot of thinking on TR. It may correct the
misguiding division of labour and timing suggested by this model, which can lead to
ineffective innovation. That being said, in the literature we analysed it often is not
very clear what type of knowledge is actually to be translated backwards and how an
effective translation could be achieved. Patients, for example, are often considered
to have ‘experiential knowledge’ of their disease, their body and how to live with
the disease. It is not obvious, however, how such knowledge can be taken up in, say,
molecular research. At this point, more work is definitely needed.
The Cause(s) of the Translational Gap
Whatever the domains in need of translation, and whatever the direction(s) trans-
lation is supposed to take, something has to be done to achieve translation. In the set
of documents we analysed two sorts of activities can be distinguished. First of all
there are activities like funding, creating new venues for publication, or changing
regulation. These activities are assumed to realize the conditions necessary for
translation—they facilitate TR. Second, TR is also identified with activities directly
related to doing biomedical research; doing research in the strict sense of designing
and performing experiments to test formulated hypotheses. Accordingly, two groups
of perceived causes of the translational gap (whatever its construction) are
identifiable: ‘external’, non-scientific causes and ‘internal’ causes found in
biomedical scientific practice itself. Of course, explanations for the translational
gap need not be mono-causal; many documents put forward a number of factors
contributing to the translational gap. For the sake of clarity, however, we will
discuss these two groups separately.
Some argue that TR is a new label referring to ‘ancient practices’ [72]. And
indeed, in our set of documents the label TR is frequently used to refer to standard
types of biomedical research like clinical trials, interventional studies or observa-
tional studies [5, 36, 41]. In cases like these, the research necessary for translation is
nothing new—it is research ‘as usual’. The dominant view in the documents we
analysed is that TR does not denote new research approaches, but existing types of
research in need of some sort of external support. The shared diagnosis in these
cases is that the translational process is obstructed by many non-scientific hurdles.
These may concern all kinds of practical, social, economic or ethical obstacles, like:
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lack of funds for expensive clinical trials, lack of communication between lab
researchers and clinicians, or strict regulation for research with human subjects,
making researchers shy away from the administrative work involved. An array of
measures is proposed to address these ‘external’ blocks and thus to stimulate TR.
Which measures are singled out depends on the characterization of the translational
gap and the translational process. Most frequently, the translational gap is localized
within the R&D-domain, within a uni-linear process of innovation. The proposed
measures then are, among others: removing (ethical) regulatory obstacles [59],
changing recruitment of research subjects [81], new ways of recruiting and training
researchers [70], stimulating collaboration between academy and industry [16],
stimulating communication between researchers and clinicians [71] and publishing
preliminary research data in journals [46].
In contrast, when the translational gap is localized between research and clinical
practice (D), other causes and activities are stressed. For example, lack of
professional awareness of the state of the art of biomedical sciences is argued to
hinder translation [23], and developing clinical guidelines is proposed as an
essential translational endeavour [18]. When the gap is located between implemen-
tation and improved health (E and F), it is for example mentioned that expenses
related to the use of a new drug impede translation, which urges insurance
companies to change their reimbursement policies [76]. Lack of backwards
translation is also frequently linked to external causes, for example because of
restricted access to results of scientific research [3]. The same goes for the general
lack of interest of medical journals for negative results [77]. For this reason, most
new journals in translational research have an open access policy and claim to
publish both positive and negative results. It is also frequently argued that research
to produce clinically relevant knowledge, such as clinical trials and observational
research, receive insufficient attention and funding [82]. From that perspective,
there is hardly anything to translate backwards in the first place.
All views identifying only external causes for the translational gap imply that
translational research in itself is not particularly difficult. It is not performed as
frequently as it should be, because this part of scientific work is expensive, time or
energy consuming. As a result, few people are willing to do the job. The point of TR
according to these views is to make translational work easier and more attractive by
removing unnecessary obstacles.
In addition to the very prevalent ‘externalist’ view, some documents identify
science itself as the main cause of the translational gap. In these cases, translation is
supposed to be difficult or impossible because scientific knowledge is not easy to
translate, and this in turn is thought to be due to the methods used in science. For
example, several authors argue that in vitro and animal models produce a type of
knowledge that does not adequately represent the complex mechanisms of the
human body [15, 51]. They argue that more complex animal models or models of
human clinical tissue are needed [55, 61], because these produce better—more
‘translatable’—knowledge.
Other authors find fault with randomized clinical trials [18, 47, 80], because these
often produce knowledge that is valid for a very specific group of patients only.
From this perspective, the translational gap is at least partly created by the
42 Health Care Anal (2015) 23:32–49
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artificiality of experimental set ups. This artificiality sits badly with the complexity
of real word settings and is expressed in the possible tension between internal and
external validity [2, 28, 80]. To overcome this cause of the translational gap, then,
we need biomedical research methods that use ‘real world’ settings and outcome
measures [80]. The use of biomarkers as surrogate endpoints is also frequently
mentioned as part of TR [30, 40, 63]. They can function as a ‘translator’ between
bodily processes and the symptoms of patients, and thus help to save time and costs
of clinical trials with clinical endpoints.
In documents identifying ‘internal’, scientific causes for the lack of translation,
TR is anything but ‘science as usual’. As NIH director Zerhouni argues, we need
‘‘truly novel approaches to and methodologies for conducting research’’ [86]. In
addition to producing more realistic research models and using real world data, a
recurrent theme is the need for convergence or (re-)integration: of different life
sciences [3], of different experimental approaches [6], of life sciences and clinical
sciences [79] and even of life sciences and all kinds of population studies [16]. Such
integration requires computational research with large databases of molecular,
clinical and epidemiological information. Better information technology systems
are therefore assumed to be a critical condition for TR—indicating that these novel
research methods, like the old ones, should be facilitated [12, 16, 85].
The views of TR starting from an ‘internalist’ explanation of the translational
gap, then, are geared towards the production of better knowledge by doing
innovative science. The resulting knowledge is supposed to be more ‘translatable’,
that is, easier to take up in other domains, both within science (for example when
using better animal models) or in clinical practice and beyond (for example by using
patients’ expertise to develop a new technology). Backwards translation can be an
important driver to develop innovative research methods, in particular when
including non-scientific expertise in discussions on the research set up.
To sum up this section: the documents we analysed identify factors both internal
and external to science as causes for the lack of translation. Of course, the boundary
between science and its context is highly porous as well as contested, so any
demarcation of ‘internal’ and ‘external’ is liable to criticism. We use the
terminology here simply to distinguish causes related to scientific methods and
the knowledge they produce from causes that do not put into question the methods
and products of current scientific work. This distinction is relevant because it
attributes roles and responsibilities to specific actors. Whereas the external views
tend to select policy makers, funders, teachers and trainers as actors who can further
the translational process, the internal views mainly look at scientific researchers and
technology developers. To be sure, many authors mention more than one cause, and
propose a mix of activities by a broad array of actors to achieve translation.
It seems indeed plausible that the lack of translations (in plural) has multifactorial
origins. If this is true, the ‘externalist’ views predominating our set of documents have
important deficiencies. These views tend to take the translatability (including the
relevance and usefulness) of the knowledge produced by science too much for granted.
The ‘internalist’ views rightly point out that the translational gap is at least partly created
by science itself. It makes sense, then, to stimulate innovative ways of science, but also
to create the financial, organizational and regulatory conditions for doing so.
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Conclusion: A New Contract Between Science and Society?
We started our analysis by observing that ‘translational research’ quickly has
become an imperative in biomedical science. The plea for TR seems driven by a
changed relationship between science and society. ‘Translation’ has become
important because society is thought to deserve a tangible return (in terms of health
and quality of life) on its investment in (often basic) biomedical science. We also
pointed out, however, that the meaning of TR should not be taken for granted. Even
though the normative justification remains similar, different views of TR circulate.
Our analysis of the scientific discourse on TR shows that it is indeed useful to
disentangle different views of TR. For each document on TR, it is useful to ask what
its position is on three dimensions. The dimensions and the possible positions are
summarized in Table 2.
The first dimension concerns the scope and the precise location(s) of the
translational gap. Narrow views of TR focus on a perceived gap in science or in
medical practice; broader views aim to address several of the narrow gaps in one
(albeit complex) move. The narrow view is dominant. Although the rather ambitious
broader view has definite weaknesses, it does clearly point out that the dominant
narrow view of TR takes too much for granted. New medical knowledge or new
medical technologies in themselves are usually not enough to realize the values of
health and quality of life.
The second dimension regards the supposed translational process. Most frequently,
the translational process is supposed to be uni-linear, proceeding from lab research to
clinical trial to practices of use. However, quite a few authors contest the implied
assumption that knowledge or technologies once produced will automatically be taken
up by the target group. They argue that some form of backwards translation should be
stimulated. We also identified more complex models picturing TR as an iterative,
multidirectional and dynamic process. Both in the bi-directional and the complex
views the usability and relevance of medical knowledge and technologies is thought to
be crucial for an effective translation process.
The third dimension deals with the perceived cause of the translational gap. The
dominant ‘externalist’ views focus on removal of obstacles for doing science. They
propose measures to facilitate scientific research that would help lab knowledge
move forward, but that scientists are reluctant to take on. The ‘internalist’ views
Table 2 The dimensions of
translational research
Dimension Positions
Scope and location of the translational gap Narrow
Broad
Model of translational process Linear
Bi-directional
Complex
Cause of the translational gap External to science
Internal to science
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argue that science itself is part of the problem, and suggest that innovative ways of
producing knowledge and technology are necessary. These views rightly point out
that the translatability of scientific results may be assumed too easily, and that
scientific methods may widen or even create a gap with clinical practice and the
world outside the lab.
The positions on the three dimensions are often interrelated. Although all
combinations might be possible in principle, in practice some combinations occur
more often than others. It is important, moreover, to note that the different views do
not necessarily exclude each other: more than one translational gap may exist, and
the cause for each gap may be multifactorial. This means that opting for a specific
view of TR is more an issue of priority setting in a specific context than of judging
truth. It is quite clear, however, that some positions are dominant. The view of TR
we encountered most frequently in the documents we studied
1. identifies a narrow gap within R&D practice,
2. assumes a linear model of innovation, and
3. locates the causes of the gap outside science.
As a result, TR is equated with phase I or II clinical trials, and the activities
proposed to stimulate TR aim to facilitate the step from animal studies to such trials.
How does this dominant view relate to the normative ideal driving TR? Is this
indeed a good way to ensure that society will benefit from its investments in
biomedical science? On the basis of our analysis, we sincerely doubt this. For a
start, by focusing on the gap between lab/animal research and clinical trials this
view takes for granted that knowledge from clinical trials will ultimately lead to
benefit for individuals and/or the public at large. Secondly, by working with a linear
model of the translation process it misses the opportunity to find out what (groups
in) society consider as benefits, inquiring which knowledge or technology is thought
to be relevant and usable. It also does not take advantage of expertise of potential
users or stakeholders. And finally, it does not look critically at the ways in which
science itself may impede translation. As a result, even if this view of TR would
succeed in stimulating more clinical trials, the knowledge produced may not lead to
tangible benefits because it does not fit with the intended users’ characteristics,
practices and, most importantly, values.
The more marginal views of TR rightly stress the importance of
1. explicit attention for the implementation of innovations in practice,
2. backwards translation and iterative innovation processes to ensure that the
resulting knowledge or technology is relevant and useable to intended users,
and of
3. a careful crafting of scientific methods to connect lab and ‘real life’ situations as
tightly as possible.
Actually, these aspects all indicate how important it is to anticipate ‘what comes
next’: if biomedical R&D should contribute to benefit for individuals and the public,
it had better continuously ask how decision making during current stages of
innovation can best reflect the characteristics and values of future users and
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stakeholders. This will enhance the ‘translatability’ of the knowledge produced, as well
as the motivation of subsequent actors to take up this knowledge in their own work.
More generally, our analysis serves as a reminder that the attempt to make
society benefit from its investment in biomedical science is laudable, but also quite
ambitious. To realize it, many different activities, by different actors, in different
settings need to be performed, to cross many different gaps. It is quite misleading/
confusing to label all these activities and contributions with one label, TR, because
it suggests that it would suffice to perform and stimulate one type of research. It may
be more helpful to think of such beneficial innovation processes in terms of a nexus
(or web) of many translational moments: moments at which the design of present
work needs to anticipate, and to be coordinated with, the requirements and
characteristics of its future contexts of use. A guarantee that public funding for
biomedical science will lead to benefits for society is impossible to give, but
continuously and consciously connecting decision making during R&D to the future
use of its results may be our best shot for harvesting such benefits.
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